OrthoPediatrics Exceeds Q1 Revenue & EBITDA Estimates, Raises 2026 Outlook
KIDS is trading near its 52-week low of $14.42 (6.5% above the low).
Summary
OrthoPediatrics reported strong first-quarter results, with revenue reaching $59.4 million, surpassing analyst estimates of $58.32 million, and adjusted EBITDA of $2.2 million, significantly beating the $913,630 consensus. The company also raised its full-year 2026 revenue guidance to a range of $263 million-$267 million, up from previous projections. This positive performance, driven by organic growth in key product areas and international sales, indicates strong operational momentum. The beat on both top and bottom lines, coupled with an improved outlook, provides a material positive signal for the company's financial trajectory, especially following the increased net losses noted in its recent 2025 annual report. Traders will be watching for sustained growth and progress towards the company's breakeven free cash flow target for 2026.
At the time of this announcement, KIDS was trading at $15.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $380.7M. The 52-week trading range was $14.42 to $23.70. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.